MTS-004 Poised to Fill an Unmet Need in the Treatment of Pseudobulbar Affect (PBA) BEIJING, China, Oct. 23, 2025 /PRNewswire/ -- METiS TechBio, a global leader in AI-driven nanodelivery and formulation innovation, today announced that its internally developed small-molecule candidate...
Hence then, the article about metis biotech announces china s first ai enabled formulation drug candidate to complete phase iii clinical trial was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( METiS BioTech announces China's First AI-Enabled Formulation Drug Candidate to Complete Phase III Clinical Trial )
Also on site :
- What to Know About Allegations of Excessive Drinking by FBI Director Kash Patel
- Trump speeds review of psychedelics after Joe Rogan texted him about ibogaine. ‘Sounds great. Do you want FDA approval? Let’s do it’
- Royals To Select Contract Of Elias Díaz